Eiger BioPharmaceuticals, Inc. (EIGR), a commercial-stage biopharmaceutical company focused on rare metabolic diseases, Wednesday said it has decided to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta or CHD.
from RTT - Before the Bell https://ift.tt/G8M3Spk
via IFTTT
No comments:
Post a Comment